|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/44 | |
| A61K 31/198 | |||
| A61K 9/00 |
| (11) | Patento numeris | 2635256 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11838922.0 |
| Europos patento paraiškos padavimo data | 2011-11-04 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-09-11 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-10-21 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2011/059466 |
| Data | 2011-11-04 |
| (87) | Numeris | WO 2012/061787 |
| Data | 2012-05-10 |
| (30) | Numeris | Data | Šalis |
| PCT/US2010/0556 | 2010-11-05 | WO |
| (72) |
BANDAK, Stephen, I., US
BLACK, Kevin, J., US
CAMPBELL, Meghan, C., US
|
| (73) |
Biotie Therapies, Inc.,
601 Gateway Boulevard, Suite 1200, South San Francisco, CA 94080,
US
|
| (54) | A2A ANTAGONISTS AS COGNITION AND MOTOR FUNCTION ENHANCERS |
| A2A ANTAGONISTS AS COGNITION AND MOTOR FUNCTION ENHANCERS |